282 related articles for article (PubMed ID: 9761116)
21. Detection and analysis of anti-latent membrane protein 2A antibodies in the sera of patients with Epstein-Barr virus associated malignancies.
Chen Y; Yao K; Sun H; Qing J; Peng GY
Chin Med J (Engl); 2005 May; 118(9):725-30. PubMed ID: 15899133
[TBL] [Abstract][Full Text] [Related]
22. Binding of the endogenously expressed Epstein-Barr virus (EBV) envelope glycoprotein gp350 with the viral receptor masks the major EBV-neutralizing epitope and affects gp350-specific ADCC.
Khyatti M; Ahmad A; Blagdon M; Frade R; Menezes J
J Leukoc Biol; 1998 Aug; 64(2):192-7. PubMed ID: 9715258
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of commercial EBV RecombLine assay for diagnosis of nasopharyngeal carcinoma.
Paramita DK; Fachiroh J; Haryana SM; Middeldorp JM
J Clin Virol; 2008 Aug; 42(4):343-52. PubMed ID: 18455473
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC).
Liu MT; Yeh CY
Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898
[TBL] [Abstract][Full Text] [Related]
25. Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity.
Khyatti M; Patel PC; Stefanescu I; Menezes J
J Virol; 1991 Feb; 65(2):996-1001. PubMed ID: 1846213
[TBL] [Abstract][Full Text] [Related]
26. Peptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 molecule.
Tanner JE; Coinçon M; Leblond V; Hu J; Fang JM; Sygusch J; Alfieri C
J Virol; 2015 May; 89(9):4932-41. PubMed ID: 25694592
[TBL] [Abstract][Full Text] [Related]
27. EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma.
Chan KH; Gu YL; Ng F; Ng PS; Seto WH; Sham JS; Chua D; Wei W; Chen YL; Luk W; Zong YS; Ng MH
Int J Cancer; 2003 Jul; 105(5):706-9. PubMed ID: 12740922
[TBL] [Abstract][Full Text] [Related]
28. Serum IgA to Epstein-Barr virus early antigen-diffuse identifies Hodgkin's lymphoma.
McAllister SC; Shedd D; Mueller NE; Chang ET; Miller G; Bhaduri-McIntosh S
J Med Virol; 2014 Sep; 86(9):1621-8. PubMed ID: 24122847
[TBL] [Abstract][Full Text] [Related]
29. Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.
Zhao B; Zhang X; Krummenacher C; Song S; Gao L; Zhang H; Xu M; Feng L; Feng Q; Zeng M; Xu Y; Zeng Y
Front Immunol; 2018; 9():932. PubMed ID: 29765376
[TBL] [Abstract][Full Text] [Related]
30. Native early antigen of Epstein-Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma.
Paramita DK; Fachiroh J; Artama WT; van Benthem E; Haryana SM; Middeldorp JM
J Med Virol; 2007 Nov; 79(11):1710-21. PubMed ID: 17854043
[TBL] [Abstract][Full Text] [Related]
31. Increased incidence of IgA antibodies to the Epstein-Barr virus-associated viral capsid antigen and early antigens in patients with chronic lymphocytic leukemia.
Dölken G; Bross KJ; Hecht T; Brugger W; Löhr GW; Hirsch FW
Int J Cancer; 1986 Jul; 38(1):55-9. PubMed ID: 3013785
[TBL] [Abstract][Full Text] [Related]
32. Establishment and characterization of Epstein-Barr virus gp350-expressing transfected human lymphoid (Raji) cell clones.
Khyatti M; Patel PC; Menezes J
Int J Cancer; 1991 Jun; 48(4):591-7. PubMed ID: 1646179
[TBL] [Abstract][Full Text] [Related]
33. Serum responses to the combination of Epstein-Barr virus antigens from both latent and acute phases in nasopharyngeal carcinoma: complementary test of EBNA-1 with EA-D.
Chow KC; Ma J; Lin LS; Chi KH; Yen SH; Liu SM; Liu WT; Chen WK; Chang TH; Chen KY
Cancer Epidemiol Biomarkers Prev; 1997 May; 6(5):363-8. PubMed ID: 9149897
[TBL] [Abstract][Full Text] [Related]
34. Analysis and significance of anti-latent membrane protein-1 antibodies in the sera of patients with EBV-associated diseases.
Xu J; Ahmad A; D'Addario M; Knafo L; Jones JF; Prasad U; Dolcetti R; Vaccher E; Menezes J
J Immunol; 2000 Mar; 164(5):2815-22. PubMed ID: 10679125
[TBL] [Abstract][Full Text] [Related]
35. [Relationship between clinical stages of nasopharyngeal carcinoma and Epstein-Barr virus antibodies Rta/IgG, EBNA1/IgA, VCA/IgA and EA/IgA].
Cai YL; Zheng YM; Cheng JR; Wang W; Zhang YN; Wang WH; Wu YS; Zhong WM; Li J; Mo YK
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Mar; 30(3):509-11. PubMed ID: 20335122
[TBL] [Abstract][Full Text] [Related]
36. Identification of GLA/SE as an effective adjuvant for the induction of robust humoral and cell-mediated immune responses to EBV-gp350 in mice and rabbits.
Heeke DS; Lin R; Rao E; Woo JC; McCarthy MP; Marshall JD
Vaccine; 2016 May; 34(23):2562-9. PubMed ID: 27085175
[TBL] [Abstract][Full Text] [Related]
37. Antibody and antibody-dependent cellular cytotoxicity responses against the BamHI A rightward open-reading frame-1 protein of Epstein-Barr virus (EBV) in EBV-associated disorders.
Tanner JE; Wei MX; Alfieri C; Ahmad A; Taylor P; Ooka T; Menezes J
J Infect Dis; 1997 Jan; 175(1):38-46. PubMed ID: 8985194
[TBL] [Abstract][Full Text] [Related]
38. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma.
Henle G; Henle W
Int J Cancer; 1976 Jan; 17(1):1-7. PubMed ID: 175020
[TBL] [Abstract][Full Text] [Related]
39. The significance of serum IgM IgA and IgG antibodies specific for Epstein-Barr virus as determined by immunoperoxidase assay in the rapid diagnosis of infectious mononucleosis.
Hadar T; Margalith M; Sagiv E; Sarov B; Sarov I
Isr J Med Sci; 1995 May; 31(5):280-3. PubMed ID: 7759222
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of serum Epstein-Barr virus envelope glycoproteins antibodies and their association with systemic autoimmune diseases.
Li HL; Zhong LY; Kang YF; Yang YL; Shi L; Zhai AX; Wu C; Zeng MS; Zhu QY
J Med Virol; 2024 Apr; 96(4):e29595. PubMed ID: 38587217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]